97 The CLL-IPI was developed in cohorts of patients dealt with with CIT and is validated in retrospective series.ninety eight–a hundred One of the 5 products, equally TP53 and IGHV provide the strongest impact on a patient’s result, and it's thus not surprising that simplified variations in the CLL-IPI incorporating https://julian318dks5.webdesign96.com/profile